Form 4: Abbott Laboratories Director Sally E. Blount Reports Acquisition of Restricted Stock Units

Director Sally E. Blount reports acquisition of 1,866 restricted stock units of Abbott Laboratories, increasing her holdings to 35,023 common shares.

Summary

• On April 26, 2024, Sally E. Blount, a director of Abbott Laboratories, reported the acquisition of 1,866 restricted stock units.
• These restricted stock units were awarded under the Abbott Laboratories 2017 Incentive Stock Program.
• The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon separation from service, death, or a change in control.
• Following the transaction, Blount's beneficial ownership of Abbott common shares increased to 35,023.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock units acquisition. It indicates confidence from the director but doesn't provide significant positive or negative information.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.
• The incentive stock program aligns the director's interests with those of the shareholders.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon the occurrence of specific events in the future.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder sentiment.

Key Dates